Current clinical management of AD encompasses topical anti-inflammatory agents (glucocorticoids, TCS; calcineurin inhibitors, TCIs), systemic immunosuppressants (e.g., cyclosporine, methotrexate) for moderate-to-severe cases, and monoclonal antibody biologics such as dupilumab (anti-IL-4Rα) that inhibit the Th2 pathway (8). The gene discussed is IL4R; the disease is Alzheimer disease.